Seyed Hamidreza Mirbehbahani

Seyed Hamidreza Mirbehbahani

Auto-generated profile, based on publicly available information

Seyed Hamidreza Mirbehbahani

Cell Biology and Anatomical Sciences, School Of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
FAFakhroddin Aghajanpour
Fakhroddin Aghajanpour
MBMahdi Eskandarian Boroujeni
Mahdi Eskandarian Boroujeni
AJAli Jahanian
Ali Jahanian
RSReza Soltani
Reza Soltani
SESamira Ezi
Samira Ezi
AAAbdollah Amini
Abdollah Amini

1 September 2021 in Neuroscience Research
Verified
Journal Article
Closed access
NENeda Eskandari
Neda Eskandari
MBMahdi Eskandarian Boroujeni
Mahdi Eskandarian Boroujeni
MAMohammad Amin Abdollahifar
Mohammad Amin Abdollahifar
APAbbas Piryaei
Abbas Piryaei
FKFariba Khodagholi
Fariba Khodagholi
YSYousef Sadeghi
Yousef Sadeghi

1 November 2020 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
RSReza Soltani
Reza Soltani
MBMahdi Eskandarian Boroujeni
Mahdi Eskandarian Boroujeni
FAFakhroddin Aghajanpour
Fakhroddin Aghajanpour
AKAysan Khatmi
Aysan Khatmi
SESamira Ezi
Samira Ezi
MHMohammad-Hasan Heidari
Mohammad-Hasan Heidari

25 July 2022 in The Canadian Journal of Psychiatry
Verified
Journal Article
Open access
SMSafoura Mohamadi
Safoura Mohamadi
MAMasoud Ahmadzad-Asl
Masoud Ahmadzad-Asl
SNSeyed Aria Nejadghaderi
Seyed Aria Nejadghaderi
RJRoxana Jabbarinejad
Roxana Jabbarinejad
SMSeyed Hamidreza Mirbehbahani
Seyed Hamidreza Mirbehbahani
FDFarnoush Davoudi
Farnoush Davoudi
Background: Obsessive-compulsive disorder (OCD) is a major mental health condition with a lifetime prevalence rate of 1.3% among adults. While placebo effects are well described for conditions such as depressive and anxiety disorders, they have not been systematically characterized in OCD. Objectives: We aimed to determine the impact of placebos in improving different symptom domains in patients with OCD. Methods: We systematically searched PubMed, EMBASE, Scopus, Web of Science, Ovid, the Cochrane Library, and Google Scholar databases/search engine from inception to January 2021 for randomized controlled trials of treatments for OCD with a placebo arm. A modified Cohen's effect size (ES) was calculated using change in baseline to endpoint scores for different measurement scales within placebo arms to estimate placebo effects and to investigate their correlates by random-effects model meta-analyses. Results: Forty-nine clinical trials (placebo group n = 1993), reporting 80 OCD specific (153 measures in general) were included in the analysis. Overall placebo ES (95% confidence interval [CI]) was 0.32 (0.22–0.41) on OCD symptoms, with substantial heterogeneity (I-square = 96.1%). Among secondary outcomes, general scales, ES: 0.27 (95%CI: 0.14–0.41), demonstrated higher ES than anxiety and depression scales, ES: 0.14 (95%CI: −0.4 to 0.32) and 0.05 (95%CI: −0.05 to 0.14), respectively. Clinician-rated scales, ES: 0.27(95%CI: 0.20–0.34), had a higher ES than self-reported scales, ES: 0.07 (95%CI: −0.08 to 0.22). More recent publication year, larger placebo group sample size, shorter follow-up duration, and younger age of participants were all associated with larger placebo ES. Egger's test reflected possible small-study effect publication bias ( P = 0.029). Conclusion: Placebo effects are modest in OCD trials and are larger in clinician ratings, for younger patients, and early in the treatment course. These findings underscore the need for clinicians and scientists to be mindful of placebo effects when formulating treatments or research trials for OCD. Systematic review registration number: PROSPERO CRD42019125979.

3 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HPHossein Pakdaman
Hossein Pakdaman
AHAli Amini Harandi
Ali Amini Harandi
KGKoroush Gharagozli
Koroush Gharagozli
FAFarshid Alaeddini
Farshid Alaeddini
AEAkram Esfandani
Akram Esfandani
HKHadi Kazemi
Hadi Kazemi
Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old [32.7 per 1000 persons (95% CI 29.1–36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.

1 October 2020 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
GMGholam Hossein Meftahi
Gholam Hossein Meftahi
MMMaral Moafi
Maral Moafi
SMSeyed Hamidreza Mirbehbahani
Seyed Hamidreza Mirbehbahani
FFFarid Fotouhi
Farid Fotouhi
HTHossein Toreyhi
Hossein Toreyhi
AAAbbas Aliaghaei
Abbas Aliaghaei